In a significant development, the World Health Organisation (WHO) has granted Emergency Use Listing (EUL) to India's COVID-19 vaccine, Corbevax, manufactured by Biological E Limited. The vaccine, based on a protein subunit platform, has already received approval from the Drugs Controller General of India (DCGI) for restricted emergency use among various age groups.
Mahima Datla, Managing Director of Biological E Ltd, expressed satisfaction with the WHO endorsement, stating, "We are confident that this endorsement from WHO will bolster our global fight against COVID-19." She highlighted the company's commitment to developing and providing access to high-quality and affordable vaccines globally, even as many other vaccine initiatives faced challenges during the pandemic.
Also Read: Weight Loss Wonder: Benefits of Eating Papaya for a Healthier You
Corbevax was initially approved for emergency use among adults, adolescents, and young children in a sequential manner from December 2021 to April 2022. Furthermore, in June 2022, it received approval as India's first heterologous COVID-19 booster shot for adults aged 18 and above. The company supplied 100 million doses to the central government, contributing to pan-India immunisation campaigns, particularly targeting children aged 12-14 years.
Also Read: Weight Loss Wonder: Benefits of Eating Papaya for a Healthier You
Biological E's continued dedication to vaccine development stands out in contrast to other companies that exited the vaccine development landscape due to funding shortages or lack of success. With the WHO Emergency Use Listing, Corbevax is poised to play a crucial role in the ongoing global efforts to combat the COVID-19 pandemic.
This recognition from WHO not only solidifies Corbevax's standing in the international community but also positions it as a vital tool in the fight against the ongoing challenges posed by the pandemic.